Abstract
BackgroundImmune checkpoint inhibitor associated arthritis (ICI-A) affects 4% of ICI-treated cancer patients and often persists, even after ICI cessation. Given its long duration, it is important to identify effective treatments...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
